Unknown

Dataset Information

0

Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation.

ABSTRACT:

SUBMITTER: Hua C 

PROVIDER: S-EPMC8390030 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.
| S-EPMC4727515 | biostudies-other
Unknown Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
| S-EPMC5061146 | biostudies-literature
Unknown Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review.
| S-EPMC6218672 | biostudies-literature
Unknown Intranasal gene therapy to prevent infection by SARS-CoV-2 variants.
| S-EPMC8282039 | biostudies-literature
Unknown Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection.
| S-EPMC8370058 | biostudies-literature
Unknown Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
| S-EPMC4170648 | biostudies-literature
Unknown Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease.
| S-EPMC8342870 | biostudies-literature
Unknown Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation.
| S-EPMC8725443 | biostudies-literature
Unknown Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
| S-EPMC5712561 | biostudies-literature
Unknown REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
| S-EPMC7857396 | biostudies-literature